

STANNINGLEY PHARMA LIMITED

**Company Registration Number:
07297580 (England and Wales)**

Unaudited abridged accounts for the year ended 30 June 2022

Period of accounts

Start date: 01 July 2021

End date: 30 June 2022

STANNINGLEY PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 30 June 2022

Balance sheet

Notes

STANNINGLEY PHARMA LIMITED

Balance sheet

As at 30 June 2022

	<i>Notes</i>	2022	2021
		£	£
Fixed assets			
Intangible assets:	3	6,519	6,519
Tangible assets:	4	12,056	3,551
Total fixed assets:		18,575	10,070
Current assets			
Stocks:		733,126	904,890
Debtors:		783,201	628,168
Cash at bank and in hand:		771,110	444,727
Total current assets:		2,287,437	1,977,785
Creditors: amounts falling due within one year:		(546,092)	(854,723)
Net current assets (liabilities):		1,741,345	1,123,062
Total assets less current liabilities:		1,759,920	1,133,132
Total net assets (liabilities):		1,759,920	1,133,132
Capital and reserves			
Called up share capital:		500	500
Share premium account:		59,900	59,900
Profit and loss account:		1,699,520	1,072,732
Shareholders funds:		1,759,920	1,133,132

The notes form part of these financial statements

STANNINGLEY PHARMA LIMITED

Balance sheet statements

For the year ending 30 June 2022 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

**This report was approved by the board of directors on 28 March 2023
and signed on behalf of the board by:**

Name: Mr Imran Khan
Status: Director

The notes form part of these financial statements

STANNINGLEY PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2022

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Tangible fixed assets and depreciation policy

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Intangible fixed assets and amortisation policy

Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at a revalued amount, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses. Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.

Valuation and information policy

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

STANNINGLEY PHARMA LIMITED

Notes to the Financial Statements for the Period Ended 30 June 2022

2. Employees

	<i>2022</i>	<i>2021</i>
Average number of employees during the period	6	4

STANNINGLEY PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2022

3. Intangible Assets

	Total
Cost	£
At 01 July 2021	6,519
At 30 June 2022	<u>6,519</u>
Net book value	
At 30 June 2022	<u>6,519</u>
At 30 June 2021	<u>6,519</u>

STANNINGLEY PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2022

4. Tangible Assets

	Total
Cost	£
At 01 July 2021	17,941
Additions	11,519
At 30 June 2022	<u>29,460</u>
Depreciation	
At 01 July 2021	14,390
Charge for year	3,014
At 30 June 2022	<u>17,404</u>
Net book value	
At 30 June 2022	<u>12,056</u>
At 30 June 2021	<u>3,551</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.